Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Type 1 Diabetes
Interventions: contingency management; Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 15 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes
Interventions: Sleep Coach, Diabetes Education; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 11 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes, Peripheral Neuropathy
Interventions: Salsalate, PLACEBO; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Type 1 Diabetes
Interventions: Liraglutide 1.8mg, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more

Conditions: Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Placebo, 10mg TZP-102, 20mg TZP-102; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Control-IQ technology 2.0; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 1
Interventions: Islet Cell Transplant, Islet Cell Transplant plus; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 13 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more

Conditions: Type 1 Diabetes, Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Atazanavir; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: 18F-FP-DTBZ (18F-AV-133), Arginine-hydrochloride; Drug · Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes, Prediabetic State, Dysglycemia, Autoimmune Diabetes
Interventions: Early CGM-guided education and initiation of insulin therapy., Usual care: glucometer surveillance and basic education.; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 20 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Observation During Exercise and Stress; Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Santa Barbara, California • Rochester, Minnesota

Conditions: Type 1 Diabetes
Interventions: Multiple daily ijnection using Insulin Degludec and Insulin Aspart; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions: CNP-103, Placebo; Drug
Lead sponsor: COUR Pharmaceutical Development Company, Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 45
States / cities: Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, t:slim X2 with Basal-IQ & Dexcom G6 CGM; Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: New-onset Type 1 Diabetes
Interventions: Ladarixin, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 1
Interventions: T1Doing Well; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 17 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Personalized Feedback, Decision Support System, Sensor Augmented Mode; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Subjects Without Type 1 Diabetes
Interventions: Continuous glucose monitor; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 8 Years and older
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: San Diego, California • Stanford, California • Aurora, Colorado + 6 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Low carbohydrate diet, Standard of care diet; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 30 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Search by objective public record fields.

A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management

Sleep Coach for Adolescents With Type 1 Diabetes

Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy

Liraglutide in Type 1 Diabetes

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

PET Scan Imaging of Beta Cell Mass

Accuracy Comparison of Two CGMs in Hospitalized Patients

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients

Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D

Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes

Insulin Pump to Multiple Daily Injection Transition Clinical Trial

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study

Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes

Sequencing T-cells in Type I Diabetes Mellitus

Continuous Glucose Sensor Profiles in Non-Diabetic Subjects

The Effects of a Low Carbohydrate, Non-Ketogenic Diet Versus Standard Diabetes Diet on Glycemic Control in Type 1 Diabetes